Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGrupo Español Multidisciplinar de Melanoma
About this trial
This is an observational, multicentre epidemiological study with a longitudinal cohort in which information will be retrieved from medical records of patients with advanced metastatic or unresectable melanoma at first diagnosis.
Eligibility criteria
Qualifiers
Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as: a. Disease onset as metastatic or unresectable disease; b. First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period.
Signing the Informed Consent Form (ICF).
A patient may have received the first or subsequent treatments for metastatic or unresectable disease in a hospital other than the centre where the ICF was signed, as long as the patient meets the inclusion criteria 1.
A patient can only sign one ICF (cannot sign an ICF in two different centres).
Disqualifiers
Any patient not complying with inclusion criteria.
Trial design
Treatments tested in this trial
- Daily Clinical Practice
Treatment groups
400 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov